Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Sinobiopharma fiscal 2010 total revenue increases 101% YoY to $7.7 million

Sinobiopharma, Inc., a fully integrated and highly innovative specialty pharmaceutical company engaged in the research, development, manufacture, and marketing of biopharmaceutical products in China, announced financial results for the fiscal year ended May 31, 2010.

22 Sep 2010

Access enters $30M supply agreement for MuGard with RHEI

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.

21 Sep 2010

Echo commences development of new transdermal biosensor for continuous lactate monitoring

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that it is beginning a development program designed to create a new transdermal biosensor for continuous lactate monitoring to be used in critical care and sports medicine.

21 Sep 2010

EffRx, Nycomed announce European filing for EX101 marketing approval

EffRx Pharmaceuticals SA and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted. The filing triggers a milestone payment to EffRx.

21 Sep 2010

USP PET results qualify Apricus Bio's NexACT as anti-microbial preservative

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that results from a United States Pharmacopeia Preservative Efficacy Test (USP PET) qualified NexACT as an anti-microbial preservative. The results show that NexACT was effective in killing more than 23 strains of bacteria, fungus and mold, well beyond the requirements for passing the USP PET.

21 Sep 2010

3M Health Care introduces Tegaderm I.V. Advanced Securement Dressing

3M Health Care today announced the launch of 3M™ Tegaderm™ I.V. Advanced Securement Dressing for patients, a comprehensive solution with transparent, breathable film, a stabilization border and new, comfort adhesive technology. The new dressing is perceived by clinicians to reduce catheter manipulation and resist staining which could lead to less frequent dressing changes, and may provide a cost savings option for hospitals.

21 Sep 2010

Elias Shaker to sell Generex's novel consumer products

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has entered into a sales agreement with Elias Shaker & Company, a leading national full-service consumer product brokerage firm, to represent Generex's novel consumer products to national and regional retail and wholesale accounts in the USA.

20 Sep 2010

Generex Biotechnology convenes Special Meeting to approve amendment

Generex Biotechnology Corporation today announced that it convened a special meeting of stockholders (the "Special Meeting") on September 17, 2010 at 10:00 a.m. (local time) at the Meeting Rooms, Westin Harbour Castle Hotel, 1 Harbour Square, Toronto, Ontario Canada M5J 1A6.

18 Sep 2010

CNSI, MESA+ collaborate to expand nanotechnology projects

The California NanoSystems Institute at UCLA and the MESA+ Institute of Nanotechnology at the University of Twente in the Netherlands have signed a memorandum of understanding to use their combined intellectual and physical resources to collaborate on projects that apply nanotechnology to problems of global concern in health and the environment.

18 Sep 2010

Emisphere’s SNAC drug successful in reducing food intake; increasing satiety

Emisphere Technologies, Inc. today announced that a clinical study found that the company's proprietary oral SNAC (Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") additive, in combination with two digestive hormones, was successful in reducing food intake and increasing satiety in healthy male subjects.

18 Sep 2010

FDA accepts to review Aricept NDA for Alzheimer's disease

Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept, a leading medication for the treatment of Alzheimer's disease.

18 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

CID to provide update on Cre8 polymer-free DES program at TCT 2010

CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".

17 Sep 2010

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

Access Pharmaceuticals launches product website for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.

15 Sep 2010

Apricus Biosciences announces reformulation of Rituxan enables rectal delivery of biologics

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced results from a pre-clinical pharmacokinetic study showing the ability of NexACT to enable rectal delivery of biologics, such as human antibodies.

15 Sep 2010

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.

14 Sep 2010

3M Health Information Systems releases ICD-10 Code Translation Tool

3M Health Information Systems, an international leader in ICD-9 and ICD-10 coding and clinical terminology management, has released the 3M ICD-10 Code Translation Tool, now fully integrated with 3M's medical vocabulary server, the 3M Healthcare Data Dictionary, to provide a single source solution for translating and converting ICD-9 based applications to ICD-10.

13 Sep 2010

Debiopharm, Aurigene commence IND enabling studies for Debio 0617 inhibitor

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.

13 Sep 2010

Diamyd Medical reports potential results on NP2 Phase I clinical trial for chronic pain

Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.

13 Sep 2010